Bayforest Capital Ltd Sells 13,803 Shares of Progyny, Inc. $PGNY

Bayforest Capital Ltd cut its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 89.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,589 shares of the company’s stock after selling 13,803 shares during the quarter. Bayforest Capital Ltd’s holdings in Progyny were worth $35,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Truist Financial Corp increased its holdings in shares of Progyny by 47.0% during the second quarter. Truist Financial Corp now owns 23,470 shares of the company’s stock worth $516,000 after purchasing an additional 7,499 shares during the period. GC Wealth Management RIA LLC bought a new position in shares of Progyny during the second quarter worth approximately $647,000. State of Alaska Department of Revenue increased its holdings in shares of Progyny by 8.2% during the second quarter. State of Alaska Department of Revenue now owns 44,425 shares of the company’s stock worth $976,000 after purchasing an additional 3,376 shares during the period. Leibman Financial Services Inc. increased its holdings in shares of Progyny by 1.1% during the second quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company’s stock worth $1,011,000 after purchasing an additional 513 shares during the period. Finally, Voya Investment Management LLC increased its holdings in shares of Progyny by 258.2% during the first quarter. Voya Investment Management LLC now owns 185,495 shares of the company’s stock worth $4,144,000 after purchasing an additional 133,703 shares during the period. 94.93% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on PGNY shares. Raymond James Financial set a $28.00 target price on shares of Progyny in a report on Friday, August 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price objective (up from $26.00) on shares of Progyny in a research note on Friday, August 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Progyny in a research note on Wednesday, October 8th. Truist Financial lifted their price objective on shares of Progyny from $24.00 to $27.00 and gave the company a “hold” rating in a research note on Thursday, July 17th. Finally, Leerink Partnrs raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Progyny has an average rating of “Moderate Buy” and a consensus price target of $25.44.

Progyny Price Performance

Shares of Progyny stock opened at $19.34 on Friday. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $26.76. The firm has a market capitalization of $1.66 billion, a P/E ratio of 32.78, a P/E/G ratio of 1.64 and a beta of 1.34. The company’s 50 day moving average price is $22.02 and its two-hundred day moving average price is $22.13.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The company had revenue of $332.87 million during the quarter, compared to analyst estimates of $315.70 million. During the same quarter in the prior year, the business earned $0.17 EPS. The business’s quarterly revenue was up 9.5% on a year-over-year basis. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current year.

Insider Buying and Selling

In other Progyny news, Director Kevin K. Gordon sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $22.04, for a total value of $55,100.00. Following the sale, the director owned 12,501 shares in the company, valued at $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Allison Swartz sold 2,398 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total transaction of $55,058.08. Following the completion of the sale, the executive vice president owned 79,697 shares in the company, valued at $1,829,843.12. This represents a 2.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,895 shares of company stock worth $179,311 in the last 90 days. Company insiders own 9.40% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.